Abdomen

Peter Magubane: courageous photographer who chronicled South Africa's struggle for freedom

Retrieved on: 
Thursday, January 4, 2024
People, African National Congress, Walking, Family, Kolkata metropolitan area, Federation, Congress Alliance, Book, Woman, Movement, Government, Defiance Campaign, Chill, Student, Population, Group Areas Act, Pain, Hope, Union Buildings, Police, Common Ground, Congress, Mouth, Black, Heart, National Party, Fruit, Arrest, Abdomen, Atrocity, Knowledge, Sharpeville massacre, Apartheid, Drum, Intention, Adoption, Courage, 1956 Treason Trial, Time, Skin

The photographer suffered great losses during apartheid.

Key Points: 
  • The photographer suffered great losses during apartheid.
  • He miraculously survived being shot 17 times below the waist at the funeral of a student activist in Natalspruit in 1985.
  • Despite the pain and suffering he witnessed and experienced, Magubane’s photographs testify to the hope that is at the heart of the struggle for a just world.

Witness to momentous events

  • He not only witnessed, but also took part in, many of the most significant events in modern South African history.
  • Referred to as the “dompas”, the document was used to control and restrict the movement of black South Africans.
  • His images focusing on life in the township were later to form the subject of several of his books.
  • He soon began to work as a photographer under the tutelage of Drum’s chief photographer and picture editor, Jürgen Schadeberg.
  • the events of that day produced the picture of the funeral as one of the central iconographic emblems of the anti-apartheid struggle.
  • Her slender hands are beautiful, and their perfect smoothness accentuates the brutal rupture where her skin has been broken.

The archive

  • In 2018 his work was exhibited in a major retrospective, On Common Ground, alongside that of another renowned South African photographer, David Goldblatt.
  • He served as Nelson Mandela’s photographer from 1990 to 1994.
  • Magubane’s indomitable spirit and compassionate vision live on through his work.


Kylie Thomas ne travaille pas, ne conseille pas, ne possède pas de parts, ne reçoit pas de fonds d'une organisation qui pourrait tirer profit de cet article, et n'a déclaré aucune autre affiliation que son organisme de recherche.

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 32, Status: Authorised

Retrieved on: 
Thursday, January 4, 2024
Medical Subject Headings, Hip, Marketing, European Commission, Shoulder, MRI, INN, Fatigue, Movement, Dopamine, ATC, Allergy, International, European, Headache, Disease, Weakness, Syndrome, Nausea, Language, Brain, Somnolence, Dizziness, L-DOPA, Ropinirole, Restless legs syndrome, Abdomen, Red, Parkinson's disease, Thigh, Select, Committee, Patient, Cell, Time, Pramipexole, Anatomy, Medicine, Vomiting, IIA, Magnetic resonance imaging, CHMP, Skin, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Urine, Medical Subject Headings, Marketing, INN, Risk, Fracture, Alkaline phosphatase, Woman, Allergy, Heart rate, Vitamin D, ATC, Hypercalcaemia, Menopause, International, Diet, Parathyroid hormone, Headache, Disease, Osteosarcoma, Nausea, Blood, Language, Calcium, Osteoblast, Palpitations, Cancer, Heart, Dizziness, Abdomen, European Medicines Agency, Spine, Back pain, Hypercalciuria, Select, System, Safety, Cardiovascular disease, Anatomy, Arthralgia, Bone fracture, Female, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Marketing, INN, Risk, Leukopenia, Woman, Nausea, DNA, Cancer, Death, Anatomy, Pancreatic serous cystadenoma, IIA, CHMP, Skin, Bone marrow, ATC, IPSS, Myeloid tissue, European, Ageing, MDS, Abdomen, Kidney, Neutrophil, Blood, Syndrome, Thigh, Patient, RNA, Medical Subject Headings, European Commission, WHO, B cell, International, Neutropenia, Language, CMML, Myelodysplastic syndrome, Thrombocytopenia, Monocyte, Select, HSCT, Medicine, Vomiting, Cytidine, Survival, Classification, Stomach, Myelocyte, Growth, Committee, AML, Acute leukemia, Medical device

Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Platinum, Artery, INN, HER2, Histology, Hypertension, Cancer, Neoplasm, Anatomy, Paclitaxel, IIA, Diarrhea, Breast, Fatigue, Breast cancer, ATC, Embolism, Bleeding, VEGF, Weakness, Abdomen, Capecitabine, Pregnancy, Human, Safety, Gynaecology, NSCLC, Patient, Medical Subject Headings, Peritoneum, EGFR, Carboplatin, International, FIGO, Nutrient, Language, Blood, Cisplatin, Rectum, Oxygen, Anthracycline, Select, Ovary, Lung cancer, Allergy, Recurrence, European Medicines Agency, Growth, Doxorubicin, Taxane

Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vegzelma, bevacizumab, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 12, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Hereditary angioedema, INN, IIA, ATC, Pain, Blood, International, Injection, Angioedema, Ageing, Bradykinin, Language, Swelling, Abdomen, Red, European Medicines Agency, Face, Select, Caregiver, Bruise, Anatomy, HAE, Skin, Erythema, Medical device

Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 12, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 12, Status: Authorised

Magnets, mating and metallic objects – cautionary tales from the MRI scanner

Retrieved on: 
Saturday, December 30, 2023
People, Magnetic resonance, Proton, MRI, Risk, Rupture, Anatomy, Explosion, Pain, Magnet, Heat, Bleeding, Field line, Eye, Wound, Skull, Abdomen, Orgasm, Death, Metal, Noise, Hospital, Schizophrenia, Patient, Iron, Paratriathlon, Radiation, Magnetic resonance imaging, Skin, Child, Medical imaging

She had attended the hospital for an MRI (magnetic resonance imaging) scan and had entered the machine with a concealed firearm.

Key Points: 
  • She had attended the hospital for an MRI (magnetic resonance imaging) scan and had entered the machine with a concealed firearm.
  • This isn’t the first time in 2023 that a firearm injury has been sustained in an MRI scanner.
  • In February a lawyer in Brazil died after the gun tucked in his waistband discharged into his abdomen.
  • MRI has a long history, in one form or another, dating back to the 1930s.

Strong magnets

  • One of the biggest risks with MRI comes from the incredibly strong magnets that are used because they are not selective in the objects they act on.
  • Also, newer models tend not to contain ferrous metals – that is, metals that can be attracted by magnets because they contain iron.
  • Similarly, a child suffered bowel perforation during an MRI after ingesting 11 small spherical magnets.

Outside the machine can be dangerous too

  • In 2018, an Indian man was killed when an oxygen cylinder he was carrying was pulled into the MRI machine, causing it to rupture and kill him.
  • Similarly, in 2021, a South Korean man died when an oxygen cylinder in the MRI room crushed his skull after the magnet pulled it into the machine he was being scanned in.

Benefits far outweigh the risks


Despite the above stories, MRI is a revolutionary diagnostic machine that has benefits that far outweigh the risks. Further modifications of MRI, such as fMRI (functional MRI), let doctors and researchers look at brain activity and observe how diseases, such as Alzheimer’s, are progressing. They are also helping researchers discover new drugs and study anatomy – including during sex and orgasm.
These revolutionary machines are extremely useful and are entirely safe when used correctly. So next time you have an MRI scan, when clinical staff ask what seems like innocent and straightforward questions, answer honestly. And tell them about anything you think may be relevant, no matter how trivial, just to be on the safe side.
Adam Taylor does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Sequana Medical submits Premarket Approval application to US FDA for alfapump® in recurrent or refractory ascites due to liver cirrhosis

Retrieved on: 
Thursday, December 28, 2023
Ascites, Quality of life, Food, NASH, Cirrhosis, Caregiver, FDA, File, Brussels Stock Exchange, Overload, Cancer, Abdomen, Paracentesis, Patient, Liver disease, Urination, Heart failure, PMA, Medical device

The alfapump received breakthrough device designation from the US FDA in 2019.

Key Points: 
  • The alfapump received breakthrough device designation from the US FDA in 2019.
  • Recurrent or refractory ascites is a severe condition characterized by the accumulation of fluid in the abdomen.
  • The current standard treatment involves therapeutic paracentesis, an invasive and burdensome procedure that drains ascites from the abdomen using a large needle over an extended period.
  • Timur Resch, Global Vice President QM/QA/RA at Sequana Medical, commented: “The submission of our Premarket Approval application to the FDA is the result of an enormous team effort and a clear demonstration of our intensive preparation to fulfil US regulatory requirements.

Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy

Retrieved on: 
Monday, December 18, 2023
Necrosis, Risk, Infection, Human, Inflammatory bowel disease, DRS, Disease, SRA, Harvard Apparatus, Colectomy, Cancer, Abdomen, University, UPMC, OTCQB, Regenerative medicine, Diverticulitis, Patient

Stephen Badylak, George Hussey and Vincent Anto at the McGowan Institute for Regenerative Medicine, a center of the University of Pittsburgh and UPMC focused on developing regenerative therapies to address organ and tissue failure.

Key Points: 
  • Stephen Badylak, George Hussey and Vincent Anto at the McGowan Institute for Regenerative Medicine, a center of the University of Pittsburgh and UPMC focused on developing regenerative therapies to address organ and tissue failure.
  • The program will focus on the use of Harvard Apparatus Regenerative Technology’s cell-based scaffold platform to repair the colon following colon resection in a rodent model of colectomy.
  • Developing a product to repair and/or regenerate the colon following colectomy will expand our pipeline and further our product portfolio for repairing and regenerating tubular organs within the gastrointestinal tract”, commented Jerry He, Harvard Apparatus Regenerative Technology 's Chief Executive Officer.
  • “The program is designed to test several versions of our cell-based scaffold technology to repair tubular organs in the digestive system.

Valo Therapeutics Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial into Sarcoma

Retrieved on: 
Wednesday, November 29, 2023
NY-ESO-1, Lung cancer, Neoplasm, Antigen, Tumor microenvironment, Immune system, Research, Sarcoma, American Cancer Society, Melanoma, Cancer, Swelling, Abdomen, Paul Ehrlich Institute, MAGE-A3, Patient, Pembrolizumab, Medical imaging

PeptiCRAd-1 is made up of ValoTx’s proprietary oncolytic virus, VALO-D102, coated with MAGE-A3 and NY-ESO-1 peptides.

Key Points: 
  • PeptiCRAd-1 is made up of ValoTx’s proprietary oncolytic virus, VALO-D102, coated with MAGE-A3 and NY-ESO-1 peptides.
  • ValoTx’s Phase I, first-in-human trial of PeptiCRAd-1 is currently in three tumor types: melanoma, triple negative breast cancer and non-small cell lung cancer.
  • These sub-types of sarcoma are particularly interesting as they have very high expression levels of our two target antigens.
  • If you are a cancer patient interested in participating in the study, please see the “For Patients” section on valotx.com for more information.